Skip to main
IRD

Opus Genetics (IRD) Stock Forecast & Price Target

Opus Genetics (IRD) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 58%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Opus Genetics is a clinical-stage biopharmaceutical company with a strong pipeline of gene therapies targeting inherited retinal diseases. The recent positive clinical update for their lead program, OPGx-BEST1, has increased the probability of success and supports the potential for future success in their other programs. With an attractive valuation and potential for significant upside with upcoming milestones and new programs, Opus Genetics is a promising investment opportunity.

Bears say

Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing therapies for inherited retinal diseases and other retinal and refractive disorders. They operate in one segment and have a pipeline of seven AAV-based programs, with ongoing clinical trials for their lead programs OPGx-LCA5 and OPGx-BEST1. While the company has a revenue-generating product and is well-positioned in its development pipeline, there are risks to achieving target price due to uncertainties in clinical trials, regulatory approvals, and potential stock price volatility. Additionally, Opus Genetics' financials show that it has incurred significant losses and may require additional financing or partnerships in the future.

Opus Genetics (IRD) has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 58% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Opus Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Opus Genetics (IRD) Forecast

Analysts have given Opus Genetics (IRD) a Buy based on their latest research and market trends.

According to 12 analysts, Opus Genetics (IRD) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Opus Genetics (IRD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.